{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:50:15Z","timestamp":1789627815676,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL094308"],"award-info":[{"award-number":["HL094308"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL094308"],"award-info":[{"award-number":["HL094308"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"DOI":"10.1038\/s44276-025-00189-4","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:44:13Z","timestamp":1761320653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medical comorbidities prognosticate survival in glioblastoma"],"prefix":"10.1038","volume":"3","author":[{"given":"Justin","family":"Bessette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Arditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Noreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kaiserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainy","family":"Wortelboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Siwik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-6207","authenticated-orcid":false,"given":"Eric T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"189_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults. a review. JAMA. 2023;329:574\u201387.","journal-title":"JAMA"},{"key":"189_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/neuonc\/noac217","volume":"25","author":"F Girardi","year":"2022","unstructured":"Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, et al. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000\u20132014 (CONCORD-3). Neuro-Oncol. 2022;25:580\u201392.","journal-title":"Neuro-Oncol"},{"key":"189_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","volume":"107","author":"M Koshy","year":"2012","unstructured":"Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107:207\u201312.","journal-title":"J Neurooncol"},{"key":"189_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, Bent MJ, van den, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459\u201366.","journal-title":"Lancet Oncol"},{"key":"189_CR5","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/neuonc\/noad169","volume":"25","author":"B Nabors","year":"2023","unstructured":"Nabors B, Portnow J, Hattangadi-Gluth J, Horbinski C. NCCN CNS tumor guidelines update for 2023. Neuro-Oncol. 2023;25:2114\u20136.","journal-title":"Neuro-Oncol"},{"key":"189_CR6","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318:2306\u201316.","journal-title":"JAMA"},{"key":"189_CR7","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev. 2020;87:102029.","journal-title":"Cancer Treat Rev"},{"key":"189_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/genes15040501","volume":"15","author":"D Roda","year":"2024","unstructured":"Roda D, Veiga P, Melo JB, Carreira IM, Ribeiro IP. Principles in the management of glioblastoma. Genes. 2024;15:501.","journal-title":"Genes"},{"key":"189_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11043-6","volume":"23","author":"M Fu","year":"2023","unstructured":"Fu M, Zhou Z, Huang X, Chen Z, Zhang L, Zhang J, et al. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer. 2023;23:544.","journal-title":"BMC Cancer"},{"key":"189_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guideline for the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170\u201386.","journal-title":"Nat Rev Clin Oncol."},{"key":"189_CR11","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3390\/cancers14133161","volume":"14","author":"NF Brown","year":"2022","unstructured":"Brown NF, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S, et al. Survival outcomes and prognostic factors in glioblastoma. Cancers. 2022;14:3161.","journal-title":"Cancers"},{"key":"189_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/neuonc\/nox012","volume":"19","author":"W Cheng","year":"2017","unstructured":"Cheng W, Zhang C, Ren X, Wang Z, Liu X, Han S, et al. Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. Neuro-Oncol. 2017;19:736\u20138.","journal-title":"Neuro-Oncol"},{"key":"189_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00401-015-1432-1","volume":"129","author":"K Aldape","year":"2015","unstructured":"Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol (Berl). 2015;129:829\u201348.","journal-title":"Acta Neuropathol (Berl)"},{"key":"189_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","volume":"5","author":"JM Unger","year":"2019","unstructured":"Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 2019;5:326.","journal-title":"JAMA Oncol"},{"key":"189_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.wneu.2015.12.096","volume":"89","author":"M Cloney","year":"2016","unstructured":"Cloney M, D\u2019Amico R, Lebovic J, Nazarian M, Zacharia BE, Sisti MB, et al. Frailty in geriatric glioblastoma patients: a predictor of operative morbidity and outcome. World Neurosurg. 2016;89:362\u20137.","journal-title":"World Neurosurg"},{"key":"189_CR16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ana.21521","volume":"64","author":"FM Iwamoto","year":"2008","unstructured":"Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64:628\u201334.","journal-title":"Ann Neurol"},{"key":"189_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1634\/theoncologist.2018-0056","volume":"24","author":"W Liu","year":"2019","unstructured":"Liu W, Qdaisat A, Yeung J, Lopez G, Weinberg J, Zhou S, et al. The Association between common clinical characteristics and postoperative morbidity and overall survival in patients with glioblastoma. The Oncologist. 2019;24:529\u201336.","journal-title":"The Oncologist"},{"key":"189_CR18","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.3171\/2020.7.FOCUS20482","volume":"49","author":"V Katiyar","year":"2020","unstructured":"Katiyar V, Sharma R, Tandon V, Goda R, Ganeshkumar A, Suri A, et al. Impact of frailty on surgery for glioblastoma: a critical evaluation of patient outcomes and caregivers\u2019 perceptions in a developing country. Neurosurg Focus. 2020;49:E14.","journal-title":"Neurosurg Focus"},{"key":"189_CR19","doi-asserted-by":"publisher","first-page":"108521","DOI":"10.1016\/j.clineuro.2024.108521","volume":"246","author":"M Michel","year":"2024","unstructured":"Michel M, Shahrestani S, Boyke AE, Garcia CM, Menaker SA, Aguilera-Pena MP, et al. Utility of combining frailty and comorbid disease indices in predicting outcomes following craniotomy for adult primary brain tumors: A mixed-effects model analysis using the nationwide readmissions database. Clin Neurol Neurosurg. 2024;246:108521.","journal-title":"Clin Neurol Neurosurg"},{"key":"189_CR20","doi-asserted-by":"publisher","first-page":"e747","DOI":"10.1016\/j.wneu.2024.01.021","volume":"183","author":"AE Jimenez","year":"2024","unstructured":"Jimenez AE, Chakravarti S, Liu J, Kazemi F, Jackson C, Gallia G, et al. The hospital frailty risk score independently predicts postoperative outcomes in glioblastoma patients. World Neurosurg. 2024;183:e747\u201360.","journal-title":"World Neurosurg"},{"key":"189_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4239\/wjd.v2.i7.108","volume":"2","author":"A Rojas","year":"2011","unstructured":"Rojas A, Gonz\u00e1lez I, Morales E, P\u00e9rez-Castro R, Romero J, Figueroa H. Diabetes and cancer: Looking at the multiligand\/RAGE axis. World J Diabetes. 2011;2:108\u201313.","journal-title":"World J Diabetes"},{"key":"189_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cytogfr.2005.01.010","volume":"16","author":"S Yakar","year":"2005","unstructured":"Yakar S, LeRoith D, Brodt P. The role of the growth hormone\/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev. 2005;16:407\u201320.","journal-title":"Cytokine Growth Factor Rev"},{"key":"189_CR23","doi-asserted-by":"publisher","first-page":"984525","DOI":"10.3389\/fonc.2022.984525","volume":"12","author":"YR Xu","year":"2022","unstructured":"Xu YR, Wang AL, Li YQ. Hypoxia-inducible factor 1-alpha is a driving mechanism linking chronic obstructive pulmonary disease to lung cancer. Front Oncol. 2022;12:984525.","journal-title":"Front Oncol"},{"key":"189_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/ANA.0000000000000339","volume":"29","author":"K Hagan","year":"2017","unstructured":"Hagan K, Bhavsar S, Arunkumar R, Grasu R, Dang A, Carlson R, et al. Association between perioperative hyperglycemia and survival in patients with glioblastoma. J Neurosurg Anesthesiol. 2017;29:21\u20139.","journal-title":"J Neurosurg Anesthesiol"},{"key":"189_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.wneu.2017.06.164","volume":"106","author":"K Barami","year":"2017","unstructured":"Barami K, Lyon L, Conell C. Type 2 diabetes mellitus and glioblastoma multiforme-assessing risk and survival: results of a large retrospective study and systematic review of the literature. World Neurosurg. 2017;106:300\u20137.","journal-title":"World Neurosurg"},{"key":"189_CR26","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","volume":"367","author":"SF Nielsen","year":"2012","unstructured":"Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792\u2013802.","journal-title":"N Engl J Med"},{"key":"189_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56574-w","volume":"9","author":"MT Carr","year":"2019","unstructured":"Carr MT, Hochheimer CJ, Rock AK, Dincer A, Ravindra L, Zhang FL, et al. Comorbid medical conditions as predictors of overall survival in glioblastoma patients. Sci Rep. 2019;9:20018.","journal-title":"Sci Rep"},{"key":"189_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00432-014-1907-9","volume":"141","author":"G Ening","year":"2015","unstructured":"Ening G, Osterheld F, Capper D, Schmieder K, Brenke C. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J Cancer Res Clin Oncol. 2015;141:1131\u20137.","journal-title":"J Cancer Res Clin Oncol"},{"key":"189_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clineuro.2015.01.006","volume":"134","author":"G Ening","year":"2015","unstructured":"Ening G, Osterheld F, Capper D, Schmieder K, Brenke C. Risk factors for glioblastoma therapy associated complications. Clin Neurol Neurosurg. 2015;134:55\u20139.","journal-title":"Clin Neurol Neurosurg"},{"key":"189_CR30","doi-asserted-by":"crossref","unstructured":"Smith HL, Wadhwani N, Horbinski C. Major Features of the 2021 WHO Classification of CNS Tumors. Neurotherapeutics. 2022;19:1691\u2013704.","DOI":"10.1007\/s13311-022-01249-0"},{"key":"189_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"189_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02532-x","volume":"22","author":"M Barz","year":"2022","unstructured":"Barz M, Bette S, Janssen I, Aftahy AK, Huber T, Liesche-Starnecker F, et al. Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?. BMC Neurol. 2022;22:32.","journal-title":"BMC Neurol"},{"key":"189_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/neuonc\/nop011","volume":"12","author":"AP Kyritsis","year":"2010","unstructured":"Kyritsis AP, Bondy ML, Rao JS, Sioka C. Inherited predisposition to glioma. Neuro-Oncol. 2010;12:104\u201313.","journal-title":"Neuro-Oncol"},{"key":"189_CR34","doi-asserted-by":"publisher","first-page":"210256","DOI":"10.1183\/16000617.0256-2021","volume":"31","author":"M Gleeson","year":"2022","unstructured":"Gleeson M, McNicholas WT. Bidirectional relationships of comorbidity with obstructive sleep apnoea. Eur Respir Rev. 2022;31:210256.","journal-title":"Eur Respir Rev"},{"key":"189_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.semradonc.2012.05.004","volume":"22","author":"G Rodrigues","year":"2012","unstructured":"Rodrigues G, Sanatani M. Age and comorbidity considerations related to radiotherapy and chemotherapy administration. Semin Radiat Oncol. 2012;22:277\u201383.","journal-title":"Semin Radiat Oncol"},{"key":"189_CR36","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel J, Edward L. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441\u20137.","journal-title":"JAMA."},{"key":"189_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/377239a0","volume":"377","author":"PL Huang","year":"1995","unstructured":"Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239\u201342.","journal-title":"Nature"},{"key":"189_CR38","first-page":"H1600","volume":"277","author":"PC Lee","year":"1999","unstructured":"Lee PC, Salyapongse AN, Bragdon GA, Shears LL, Watkins SC, Edington HDJ, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J. 1999;277:H1600\u20138.","journal-title":"Am J"},{"key":"189_CR39","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1291\/hypres.30.1159","volume":"30","author":"R Rodrigo","year":"2007","unstructured":"Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, B\u00e4chler JP. Relationship between oxidative stress and essential hypertension. Hypertens Res Off J Jpn Soc Hypertens. 2007;30:1159\u201367.","journal-title":"Hypertens Res Off J Jpn Soc Hypertens"},{"key":"189_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/biom11040585","volume":"11","author":"AF Prado","year":"2021","unstructured":"Prado AF, Batista RIM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases and arterial hypertension: role of oxidative stress and nitric oxide in vascular functional and structural alterations. Biomolecules. 2021;11:585.","journal-title":"Biomolecules"},{"key":"189_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2015.01.010","volume":"359","author":"JV Joseph","year":"2015","unstructured":"Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, et al. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1\u03b1\u2013ZEB1 axis. Cancer Lett. 2015;359:107\u201316.","journal-title":"Cancer Lett"},{"key":"189_CR42","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/nu11092090","volume":"11","author":"T Senoner","year":"2019","unstructured":"Senoner T, Dichtl W. Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients. 2019;11:2090.","journal-title":"Nutrients"},{"key":"189_CR43","first-page":"151","volume":"10","author":"R D\u00fcsing","year":"2016","unstructured":"D\u00fcsing R. Pharmacological interventions into the renin\u2013angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering. Ther Adv. Cardiovasc Dis. 2016;10:151\u201361.","journal-title":"Cardiovasc Dis"},{"key":"189_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11605-007-0403-9","volume":"12","author":"R Anandanadesan","year":"2008","unstructured":"Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II Type 1 Receptor and ERK1\/2 Signaling. J Gastrointest Surg. 2008;12:57\u201366.","journal-title":"J Gastrointest Surg"},{"key":"189_CR45","doi-asserted-by":"publisher","first-page":"119118","DOI":"10.1016\/j.lfs.2021.119118","volume":"270","author":"N Khoshghamat","year":"2021","unstructured":"Khoshghamat N, Jafari N, Toloue-pouya V, Azami S, Mirnourbakhsh SH, Khazaei M, et al. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Life Sci. 2021;270:119118.","journal-title":"Life Sci"},{"key":"189_CR46","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/ph13120470","volume":"13","author":"Y Funakoshi","year":"2020","unstructured":"Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, et al. Update on chemotherapeutic approaches and management of bevacizumab usage for glioblastoma. Pharmaceuticals. 2020;13:470.","journal-title":"Pharmaceuticals"},{"key":"189_CR47","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/HYPERTENSIONAHA.115.03624","volume":"66","author":"CN Young","year":"2015","unstructured":"Young CN, Davisson RL. Angiotensin-II, the brain, and hypertension: an update. Hypertension. 2015;66:920\u20136.","journal-title":"Hypertension"},{"key":"189_CR48","first-page":"17","volume":"23","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Han Z, Zhu Y, Chen J, Li W. Role of hypoxia inducible factor-1 in cancer stem cells. Mol Med Rep. 2021;23:17.","journal-title":"Mol Med Rep"},{"key":"189_CR49","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/jcm13051512","volume":"13","author":"F Pasqualetti","year":"2024","unstructured":"Pasqualetti F, Gabelloni M, Faggioni L, Aquaro GD, Vietro FD, Mendola V, et al. Glioblastoma and internal carotid artery calcium score: a possible novel prognostic partnership? J Clin Med. 2024;13:1512.","journal-title":"J Clin Med"},{"key":"189_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0304-3835(03)00159-9","volume":"195","author":"D LeRoith","year":"2003","unstructured":"LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127\u201337.","journal-title":"Cancer Lett"},{"key":"189_CR51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3727\/096504016X14732772150389","volume":"25","author":"H Wang","year":"2017","unstructured":"Wang H, Tang C, Na M, Ma W, Jiang Z, Gu Y, et al. miR-422a inhibits glioma proliferation and invasion by targeting IGF1 and IGF1R. Oncol Res. 2017;25:187\u201394.","journal-title":"Oncol Res"},{"key":"189_CR52","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11060-023-04485-2","volume":"165","author":"AH Mohammad","year":"2023","unstructured":"Mohammad AH, Jatana S, Ruiz-Barerra MA, Khalaf R, Al-Saadi T, Diaz RJ. Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing. J Neurooncol. 2023;165:209\u201318.","journal-title":"J Neurooncol"},{"key":"189_CR53","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/neuonc\/noad117","volume":"25","author":"EK Noch","year":"2023","unstructured":"Noch EK, Palma LN, Yim I, Bullen N, Qiu Y, Ravichandran H, et al. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro-Oncol. 2023;25:2165\u201376.","journal-title":"Neuro-Oncol"},{"key":"189_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccell.2016.09.008","volume":"30","author":"GR Villa","year":"2016","unstructured":"Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, et al. An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. Cancer Cell. 2016;30:683\u201393.","journal-title":"Cancer Cell"},{"key":"189_CR55","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/CAD.0000000000001533","volume":"34","author":"AZ Alrosan","year":"2023","unstructured":"Alrosan AZ, Heilat GB, Al Subeh ZY, Alrosan K, Alrousan AF, Abu-Safieh AK, et al. The effects of statin therapy on brain tumors, particularly glioma: a review. Anticancer Drugs. 2023;34:985\u201394.","journal-title":"Anticancer Drugs"},{"key":"189_CR56","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/brain\/aww046","volume":"139","author":"KL Pitter","year":"2016","unstructured":"Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139:1458\u201371.","journal-title":"Brain"},{"key":"189_CR57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamaneurol.2018.4530","volume":"76","author":"ET Wong","year":"2019","unstructured":"Wong ET, Swanson KD. Dexamethasone\u2014friend or foe for patients with glioblastoma? JAMA Neurol. 2019;76:247\u20138.","journal-title":"JAMA Neurol"},{"key":"189_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","volume":"151","author":"MM Grabowski","year":"2021","unstructured":"Grabowski MM, Sankey EW, Ryan KJ, Chongsathidkiet P, Lorrey SJ, Wilkinson DS, et al. Immune suppression in gliomas. J Neurooncol. 2021;151:3\u201312.","journal-title":"J Neurooncol"},{"key":"189_CR59","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17:5473\u201380.","journal-title":"Clin Cancer Res"},{"key":"189_CR60","first-page":"4834","volume":"26","author":"JP Spano","year":"2008","unstructured":"Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol Off J Am Soc. Clin Oncol. 2008;26:4834\u201342.","journal-title":"Clin Oncol"},{"key":"189_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11060-022-04046-z","volume":"159","author":"J Weller","year":"2022","unstructured":"Weller J, Sch\u00e4fer N, Schaub C, Potthoff AL, Steinbach JP, Schlegel U, et al. Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG\/NOA-09 and GLARIUS. J Neurooncol. 2022;159:95\u2013101.","journal-title":"J Neurooncol"},{"key":"189_CR62","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-020-03625-2","volume":"149","author":"M Schneider","year":"2020","unstructured":"Schneider M, Potthoff AL, Scharnb\u00f6ck E, Heimann M, Sch\u00e4fer N, Weller J, et al. Newly diagnosed glioblastoma in geriatric (65\u2009\u2009+\u2009) patients: impact of patients frailty, comorbidity burden and obesity on overall survival. J Neurooncol. 2020;149:421\u20137.","journal-title":"J Neurooncol"},{"key":"189_CR63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.mam.2019.02.002","volume":"66","author":"S Alarc\u00f3n","year":"2019","unstructured":"Alarc\u00f3n S, Niechi I, Toledo F, Sobrevia L, Quezada C. Glioma progression in diabesity. Mol Aspects Med. 2019;66:62\u201370.","journal-title":"Mol Aspects Med"},{"key":"189_CR64","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-17-3287","volume":"78","author":"BJ Caan","year":"2018","unstructured":"Caan BJ, Cespedes Feliciano EM, Kroenke CH. The importance of body composition in explaining the overweight paradox in cancer\u2014counterpoint. Cancer Res. 2018;78:1906\u201312.","journal-title":"Cancer Res"},{"key":"189_CR65","doi-asserted-by":"publisher","first-page":"115027","DOI":"10.1016\/j.addr.2023.115027","volume":"200","author":"R Wahab","year":"2023","unstructured":"Wahab R, Hasan MM, Azam Z, Grippo PJ, Al-Hilal TA. The role of coagulome in the tumor immune microenvironment. Adv Drug Deliv Rev. 2023;200:115027.","journal-title":"Adv Drug Deliv Rev"},{"key":"189_CR66","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41416-022-01968-3","volume":"127","author":"S Koizume","year":"2022","unstructured":"Koizume S, Miyagi Y. Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications. Br J Cancer. 2022;127:2099\u2013107.","journal-title":"Br J Cancer"},{"key":"189_CR67","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1055\/s-0036-1598005","volume":"43","author":"B Bikdeli","year":"2017","unstructured":"Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? a systematic review. Semin Thromb Hemost. 2017;43:849\u201363.","journal-title":"Semin Thromb Hemost"},{"key":"189_CR68","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/01.CIR.0000136587.68725.8E","volume":"110","author":"AS Gami","year":"2004","unstructured":"Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110:364\u20137.","journal-title":"Circulation"},{"key":"189_CR69","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2006.08.060","volume":"49","author":"AS Gami","year":"2007","unstructured":"Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49:565\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"189_CR70","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacc.2013.03.052","volume":"62","author":"AS Fein","year":"2013","unstructured":"Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. JACC. 2013;62:300\u20135.","journal-title":"JACC"},{"key":"189_CR71","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamacardio.2018.0095","volume":"3","author":"D Linz","year":"2018","unstructured":"Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, L\u00e9vy P, et al. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiol. 2018;3:532\u201340.","journal-title":"JAMA Cardiol"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00189-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00189-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00189-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:02:15Z","timestamp":1761321735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00189-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["189"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00189-4","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data published in this manuscript contain no identifiable patient information or individual details, ensuring that patient anonymity is preserved. No informed consent was needed per institutional review board because this is a retrospective analysis without any patient identifiers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The analysis of the patient database at Brown University Health Cancer Institute was performed in accordance with the Declaration of Helsinki and under an institutional review board approved protocol #218622. No informed consent was needed per institutional review board because this is a retrospective analysis without any patient identifiers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"75"}}